Form 4: iRhythm Executive Granted 10,034 RSUs

iRhythm Holdings, Inc. Chief Medical/Scientific Officer Minang Turakhia was granted 10,034 Restricted Stock Units.

Summary

• Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology at iRhythm Holdings, Inc., acquired 10,034 shares of Common Stock.
• The acquisition occurred on February 25, 2026, at a price of $0 per share.
• These securities are Restricted Stock Units (RSUs), with each RSU representing a contingent right to receive one share of the Issuer's Common Stock.
• 25% of the RSUs will vest on March 1, 2027, and an additional 25% on each subsequent one-year anniversary, contingent on continued service.
• Following this transaction, Minang Turakhia beneficially owns 58,933 shares.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine, slightly positive event, reflecting standard executive compensation practices designed to retain key talent and align interests with long-term company performance.

Positives

• Grant of 10,034 Restricted Stock Units to a key executive, aligning management's interests with long-term shareholder value.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and structured equity award.

Future Outlook

The vesting schedule for the Restricted Stock Units extends into future years, with 25% vesting annually starting March 1, 2027, contingent on the executive's continued service.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units, are a standard component of executive compensation packages in the medical technology and healthcare sectors. This practice aims to incentivize long-term performance and align executive interests with shareholder value, a common strategy seen across companies like Medtronic or Abbott Laboratories.

Comparison to Industry Standards

• The grant of RSUs at a $0 price is standard practice for equity compensation, aligning with typical executive incentive structures in the healthcare technology industry.
• A four-year vesting schedule (25% annually) is a common industry standard for executive equity awards, comparable to practices at companies such as Dexcom or Insulet Corporation, designed to promote long-term retention and performance.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the executive's long-term interests with shareholder value, potentially fostering sustained performance.
• Employees: Reflects the company's compensation strategy for key personnel, which can influence overall employee morale and retention strategies.

Next Steps

• 25% of the granted Restricted Stock Units will vest on March 1, 2027.
• Subsequent 25% portions of the RSUs will vest on each one-year anniversary thereafter, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new information that would fundamentally alter the investment thesis for iRhythm Holdings, Inc. Therefore, a 'hold' recommendation is appropriate as this event alone is unlikely to drive significant stock price movement or change the company's underlying fundamentals.

Keywords

iRhythm Holdings, IRTC, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Minang Turakhia, SEC Form 4, Equity Grant